





Background: Approximately 75% of all breast cancer diagnoses are oestrogen 
receptor  (ER) positive. In such ER positive subtypes, anti-hormones such 
as fulvestrant and tamoxifen are a mainstay therapy. However, the e!cacy of 
these agents is severely limited by subsequent development of resistance. The 
glucocorticoid receptor (GR) has been implicated as a possible resistance mechanism 
owing to transcription of pro-proliferative and anti-apoptotic genes in breast 
cancer cells. A similar contributory role to resistance has also been observed in 
anti-hormone resistant prostate cancer suggested by increased GR expression and 
tumour progression. These associations are of particular concern given the use of 
glucocorticoids as an adjuvant treatment in breast cancer. This research aims to assess 
the impact of fulvestrant and tamoxifen on GR expression in the anti-hormone 
treated and resistant MCF-7 ER positive breast cancer cell line.
Methods:  mRNA and protein expression of the GR were investigated by reverse 
transcription polymerase chain reaction and Western blotting respectively, in the ER 
positive MCF-7 breast cancer cell line. Expression in wild-type cells was compared 
to cells following short-term (7 day) oestrogen (1nM) and fulvestrant (100nM) 
treatment, and in cells with acquired resistance to fulvestrant and tamoxifen. 
Results: Both fulvestrant treated and resistant MCF-7 cells exhibited increased GR 
mRNA and protein expression which was statistically signi"cant in resistant cells at 
the protein (p=0.0345) but not mRNA level. Tamoxifen-resistant cells also exhibited 
increased GR protein expression.
Conclusion: These data demonstrate up-regulation of the GR during treatment 
with, and following acquisition of resistance to, the anti-hormone fulvestrant. This 
supports potential for increased expression of GR-regulated pro-survival genes in 
resistance, indicating a potential role for the GR in anti-hormone resistant breast 
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Worldwide, breast cancer is the most common malignancy in 
females, and a signi"cant health burden, accounting for 627,000 
deaths in 2018. (1) Approximately 75% of breast cancers express or 
overexpress the ER isoform designating them ER positive (2-4) and 
sensitive to the proliferative drive of oestrogens. (2) The central role 
played by oestrogen in breast cancer progression has denoted anti-
oestrogens a mainstay in the therapeutic armamentarium against 
ER positive disease. However, the clinical utility of these agents 
is confounded by acquisition of resistance in approximately 40% 
of initially responsive adjuvant patients, (5) and 25% of all breast 
cancer cases. (6) 
Availability of anti-oestrogens has nonetheless revolutionised disease 
prognosis. For example, the selective oestrogen receptor modulator 
(SERM) tamoxifen contributed to the nearly 50% annual reduction 
in breast cancer recurrence and 30% survival improvement 
observed in the last 20 years. (6) However, as a competitive 
inhibitor of the ER, (7) tamoxifen retains the potential to function 
as an agonist, (8) as observed in bone and endometrial tissue. (9) 
These experiences prompted development of newer endocrine 
agents, such as aromatase inhibitors, which interfere with oestrogen 
production by the aromatase enzyme, and selective oestrogen 
receptor down-regulators (SERDs) such as fulvestrant (Faslodex ®). 
Fulvestrant (Faslodex ®) is recommended by the National Institute 
for Health and Care Excellence (NICE) in post-menopausal 
women with locally advanced or relapsed metastatic ER positive 
breast cancer, who have previously been treated with aromatase 
inhibitors, or have developed treatment resistance. (10) In contrast 
to tamoxifen, fulvestrant is a pure ER antagonist, devoid of the 
adverse pharmacology and sequelae re$ective of tamoxifen’s 
agonistic potential. (11) Mechanistically it exhibits widespread 
actions including inhibition of ER binding oestrogen and co-
activator proteins, decreased nuclear translocation of ligand-bound 
ER, reduced capability of ER:ERE interactions, and inhibition of 
ER dimerisation by induction of receptor conformational changes. 
(8) It is also unique in that it enhances ER degradation. (8) Hence, 
by down-regulating the ER, fulvestrant abrogates transcription 
of oestrogen-regulated target genes by both inhibiting oestrogen-
dependent signaling and preventing oestrogen-independent ER 
activation. (7,12)
Mechanisms of acquired anti-hormone resistance
Gradual loss of endocrine responsiveness occurs in the majority of 
patients treated with endocrine agents within 2-3 years. (4) Loss of 
ER expression has been postulated as a causative factor, although 
this appears unlikely given the majority of resistant tumours retain 
a functional ER, and demonstrate responsiveness to subsequent 
endocrine therapies. (13) An alternative hypothesised mechanism 
is interference mediated by other receptors. In particular, growth 
factor receptors such as human epidermal growth factor receptor 
2 (HER2) have been extensively studied and as such established a 
precedent for receptor cross-talk in the induction of anti-hormone 
resistance. (14) However, since concomitant HER2 blockade with 
monoclonal antibodies fails to appease resistance development, (15) 
involvement of other receptors is indicated.
Recent studies have implicated nuclear steroid hormone receptors 
such as the glucocorticoid receptor (GR). Indeed, increased GR 
expression has been associated with anti-hormone resistance and 
tumour progression in prostate cancer, another predominantly 
hormone driven malignancy. (16) Similarly, in ER-negative breast 
cancer one study demonstrated that high GR expression is related 
to poor prognosis and increased relapse rates, (17) a signi"cant 
"nding given mechanistically fulvestrant generates an ER-negative 
cancer, particularly when resistance develops. (8) There is however 
a paucity of data investigating the role of the GR in ER-positive 
breast cancer which this study aims to address.
The GR in breast cancer 
The anti-in$ammatory properties of glucocorticoids (GCs), such 
as dexamethasone, position them an attractive and commonly used 
agent in breast cancer (18,19) which is potentially concerning if the 
GR is implicated in resistance as we hypothesise. However, this 
bene"t appears to be cell-type-speci"c, (20) with anti-apoptotic 
functioning observed in mammary epithelial cells. (20,21) 
For example, dexamethasone treatment increases expression 
of the well-established anti-apoptotic, pro-proliferative gene 
serum-and-glucocorticoid-inducible-kinase-1 (SGK-1). (21) 
Signi"cantly, SGK-1 overexpression has recently been cited as 
causal in anti-hormone resistance in prostate cancer (22) and 
found to abrogate apoptosis in mammary epithelial cells. (23) 
Similarly, dexamethasone induces up-regulation of the anti-
apoptotic phosphatase enzyme MAPK phosphatase-1 (MKP-1). 
(24) Overexpression of MKP-1/DUSP-1 has been documented in 
breast and prostate carcinomas (24) and also ovarian cancer where 
it is associated with reduced progression free survival. (25) Such a 
pro-survival role for the GR in breast cancer is further supported 
by investigations of xenogra% tumours of mice given systemic 
GCs, demonstrating increased mRNA expression of both SGK-1 
and MKP-1, in addition to other anti-apoptotic genes. (24) Taken 
together, this evidence strongly implicates GR-regulated genes as 
mediators of breast tumour cell survival and suggests a role for the 
GR in the acquisition of endocrine resistance. This has particularly 
concerning implications regarding dexamethasone use in breast 
cancer patients.
Aims
The project evaluates the hypothesis that fulvestrant resistant 
ER-positive breast cancer cells display increased GR expression 
which theoretically would result in up-regulation of pro-survival 
genes, evidencing a clear role for the GR in the acquisition of anti-
hormone resistance in breast cancer. The expression pro"le of the 
GR will be evaluated in ER-positive MCF-7 breast cancer cell line 
and compared between wild-type, oestrogen-treated, fulvestrant-
treated, fulvestrant-resistant and in certain cases tamoxifen-
resistant cells. This cell line was chosen as the ER-positive subtype 







Cell culture and lysis 
Oestrogen-receptor positive MCF-7 (AstraZeneca 
Pharmaceuticals, Maccles"eld, UK) wild-type cells were grown 
and maintained in 5% Carbon dioxide, at 37°C, in red RPMI-1640 
medium, containing Penicillin-streptomycin (10IU/ml-10µg/ml), 
Fungizone ® (amphotericin B, 2.5µg/ml) and 5% foetal calf serum 
(FCS). 
Cultured wild-type cells were incubated for 24 hours in phenol 
red-free RPMI containing L-glutamine (200nM), 5% FCS, 
and antibiotics. Cells were then incubated for 7 days in media 
containing either oestradiol (1nM in ethanol), fulvestrant (100nM 
in ethanol), or media alone, producing 7-day-oestrogen treated, 
7-day-fulvestrant-treated and control/wild-type cells respectively. 
The in$uence of lengthened anti-hormone exposure, as 
experienced in clinical practice, was investigated using fulvestrant 
and tamoxifen resistant MCF-7 cells. Such cells were generated 
by culturing wild-type MCF-7 cells in white RPMI media 
containing inactivated FCS and fulvestrant (Faslodex ®, 100nM) 
or 4-hydroxytamoxifen (100nM) respectively, for a minimum 
6-month period. 
Cultured cells were then lysed following three washes with 
phosphate bu#ered saline (PBS) by exposure to Halt Protease and 
Phosphatase Inhibitor Cocktail and ice-cold lysis bu#er (Appendix 
A). Lysis product was transferred to eppendorfs, centrifuged (13 
000 RPM, 4°C, 15 minutes), and stored at -20°C.
RNA isolation, ampli!cation and detection
RNA samples were extracted from culture growing cells using 
a Tri® Reagent RNA Isolation Kit (Sigma-Alrich, Gillingham, 
UK). Absorbance of samples (1 in 200 dilutions) was measured 
using a CECIL CE 2041 spectrophotometer (Cecil Instruments, 
Cambridge, UK) at 260 and 280nm to determine total 
concentration. 
The instability of isolated RNA demands it be reverse transcribed 
into relatively stable complementary DNA (cDNA) prior to 
ampli"cation with Polymerase Chain Reaction (PCR). As such, 
1µg of RNA sample and 11µl of RNA mastermix (Appendix B) 
were mixed in a sterile eppendorf and then denatured at 95°C for 
5 minutes in a PCR thermal cycler (Techne TC-3000X, Bibby 
Scienti"c Ltd., Stone, UK). M-MLV reverse transcriptase and 
RNAase inhibitor (Fisher, UK) were added to the Eppendorf and 
the mixture reverse transcribed in the above machine (parameters in 
Appendix B) to form cDNA (stored at -20°C). 
PCR was used to amplify small amounts of speci"c GR cDNA 
fragments using primer pairs (sequences in Appendix B). As with 
Western blotting, actin was used for control purposes. 0.5µl of 
cDNA from each treated cell sample was added to a PCR master-
mix solution (Appendix B) to yield 4 samples: MCF-7 control 
(wild-type), MCF-7 oestrogen-treated, MCF-7 fulvestrant-
treated and master-mix control (no cDNA), the latter to check 
for contamination. A%er centrifugation, samples were placed in a 
thermocycler at varying cycle numbers and parameters (Appendix 
B) determined by experimental optimisation. 7µl of each PCR 
product mixed with 5 µl of loading bu#er (Appendix B) were 
loaded into the wells of a 2% agarose gel (Appendix B) containing 
RedSafe Nucleic Acid staining dye. The gel was run at 100V for 
30 minutes using a Bio-Rad PowerPac. Once run, bands on the 
gel were visualised using G:Box (Syngene, Cambridge, UK) and 
Genesys so%ware (Syngene, Cambridge, UK).
Protein separation and expression
Protein contents of lysed cells were separated using Sodium 
Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE); 
see Appendix A for components of resolving gel, stacking gel and 
electrode running bu#er. A total protein concentration of 20µg was 
analysed, mixed with an equal volume of loading bu#er (Laemmli 
sample bu#er [2x] with dithiothreitol [DTT]) (Appendix A). 
Once separated by SDS-PAGE, di#erential protein expression 
in the variably treated MCF-7 cell samples was assessed using 
Western blotting. Separated proteins were transferred from fragile 
gel medium to a solid nitrocellulose membrane by soaking in 
transfer bu#er (Appendix A) and running at 100V for 1 hour. The 
nitrocellulose membrane was then submerged in Ponceau S stain for 
30 seconds and washed in 1x Tris-bu#ered saline (TBS)-Tween 20 
(Appendix A) prior to incubation with primary antibody speci"c to 
the protein of interest, in this case the GR and a actin control (New 
England Biolabs Ltd, UK) (Appendix C). A 1:1000 rabbit primary 
antibody dilution made in 1% Marvel milk solution made up in 
1x TBS-Tween 20 was used. The membrane was subsequently 
incubated with secondary antibody (1:5000 IgG horseradish 
peroxidase [HRP] conjugated anti-rabbit antibody), speci"c for the 
Fc region of the primary antibody, to allow protein visualisation 
upon chemiluminescent exposure. 100µl of chemiluminescent 
detection reagents (Appendix A) were applied to the nitrocellulose 
membrane. The G:Box (Syngene, Cambridge, UK) and GeneSys 
so%ware were used to visualise protein bands.
Statistical Analysis
Where applicable, densitometry using ImageJ quanti"cation 
so%ware (U.S. National Institutes of Health) was used to analyse 
PCR and western blot bands. Statistically signi"cant di#erences 
were assessed using the student’s unpaired t-test and GraphPad 





Fulvestrant treatment increases GR mRNA expression in MCF-
7 cells. GR mRNA levels in MCF-7 breast cancer cell lines 
were compared by RT-PCR between cells given: no treatment 
(control/wild-type cells); 7-days of fulvestrant (100nM), or 7-days 
of oestrogen (1nM). Oestrogen-treated cells were included 
to provide the greatest di#erential for ER activity relative to 
fulvestrant. 7-day-fulvestrant-treatment visually up-regulated GR 
expression (Figure 1), though this was not statistically signi"cant 
(Figure 2). 
Increased GR mRNA expression is maintained in MCF-7 cells 
with acquired fulvestrant resistance.7-days of fulvestrant therapy 
is insu!cient to evoke acquisition of a fulvestrant resistant 
phenotype, given clinically resistance does not manifest until 
2-3 years a%er therapy initiation. (7) GR involvement in anti-
hormone resistance thus demands increased GR mRNA be 
sustained in fulvestrant-resistant cells.  GR mRNA expression was 
up-regulated in fulvestrant-resistant versus wild-type MCF-7 cells 
(Figure 3). Di!culties obtaining PCR bands in this resistant cell 
sample precluded densitometry (n=1). 
GR protein expression is increased in fulvestrant and tamoxifen 
resistant MCF-7 cells .GR mRNA alterations must translate to the 
protein level to confer biological signi"cance. Thus, GR protein 
expression in wild-type (control) MCF-7 cells was compared 
to 7-day-fulvestrant-treated (Fas), tamoxifen-resistant (Tam-R) 
and fulvestrant-resistant (Fas-R) cells. GR protein (94kDa) 
was expressed in all control and treated cells, and unequivocally 
increased in fulvestrant-resistant, tamoxifen-resistant and 7-day-
fulvestrant-treated cells relative to control, though the increase was 
most pronounced in anti-hormone resistant cell samples, evidenced 
by markedly denser bands in both fulvestrant and tamoxifen 
resistance (Figure 4). The increase in GR protein in fulvestrant-
resistant cells was statistically signi"cant (p=0.0345) compared to 







Since 1977, breast cancer has been the most prevalent cancer in 
females within the United Kingdom with approximately 75% of 
cases ER-positive. (26) The e!cacy of anti-hormone agents such 
as fulvestrant is limited by development of resistance in a large 
cohort of patients. (4) Numerous underlying mechanisms have 
been postulated but, as of yet, fail to fully explain this acquisition 
of resistance. (27) Accordingly, this study investigated the potential 
role of the GR in driving resistant cell growth in the ER positive 
MCF-7 breast cancer cell line, with the aim of better understanding 
the resistance process.
At the mRNA level, alterations in GR expression in both 
7-day-fulvestrant treated and fulvestrant-resistant cells were not 
statistically signi"cant. Considering up-regulation was signi"cant 
in resistance at the protein level, this may re$ect the small sample 
size (n=3) of the study. Alternatively, particularly regarding 7-day-
treated cells, it implies that transcriptional alterations require longer 
to manifest, and so do not become apparent until later on in the 
resistance process. This is not wholly unreasonable, given clinical 
indications of acquired resistance are only apparent 2-3 years a%er 
commencement of therapy. (4, 28)
In the present study, a meaningful contribution of the GR in 
endocrine resistance was suggested by observation of potent and 
statistically signi"cant increase in GR protein up-regulation in 
fulvestrant-resistance. Tamoxifen-resistant cells also exhibited an 
increase in GR protein, though this was not statistically signi"cant 
and could be re$ective of the small sample size or a non-genuine 
change. In the ER positive MCF-7 cell line, other authors have 
observed reduced GR levels when compared to expression in ER 
negative cells, (29) which has subsequently been shown to result 
from oestrogen suppression of GR. (30-32) Therefore, the GR up-
regulation observed in fulvestrant-resistant cells in this study may 
in part be explained by the essentially ER negative status, conferred 
by fulvestrant-mediated down-regulation of ER. (8) Interestingly, 
high GR expression in ER negative disease is also linked to worse 
disease free survival. (14) Hence, fulvestrant degradation of ER 
plausibly accounts for both the observed increase in GR with anti-
hormone therapy and the negative clinical implications of this in 
terms of resistance.
Notably, the phenomenon of anti-hormone-induced GR up-
regulation is not unique to breast cancer. Similar patterns have 
been observed in other, also predominately hormone-driven 
malignancies, such as prostate cancer, (33) with pharmacological 
androgen receptor (AR) blockade circumventing AR repression of 
GR levels, resulting in GR up-regulation. (34) 
Dexamethasone, a GC, is routinely used alongside anti-hormones 
in breast cancer as a potent analgesic, or to relieve cancer-associated 
in$ammatory symptoms. (20) Hence, implication of GR-mediated 
GC-induced transcription of survival genes in breast cancer has 
concerning implications surrounding the clinical worth of adjuvant 
GCs. (35, 36) Speculatively, if anti-hormone resistance is indeed 
stimulated by the GR, current practice of administering exogenous 
agonists such as dexamethasone, whilst bene"cial in the short-term, 
could be having an overall detrimental impact. Hence, there is an 
urgent need for a prospective randomised controlled clinical trial 
investigating the e#ect of concomitant use of, and pre-treatment 
with, GCs. 
The importance of ameliorating treatment-induced side e#ects 
cannot be downplayed. However, given the uncertainty of GCs 
in breast cancer, perhaps a di#erent and safer approach should be 
employed, for example non-steroidal anti-in$ammatory drugs. 
(37) Alternatively, concomitant use of anti-hormones with a GR 
antagonist, such as mifepristone, may show promise in delaying or 
preventing resistance, (38) though this needs further investigation. 
Furthermore, in experimental models of prostate cancer, the 
GR gene product SGK-1 was inhibited, resulting in reversal of 
resistance to androgen therapy. (34) Indeed, this may be superior 
to systemically administered GR inhibitors which would inevitably 
have widespread undesirable e#ects. 
The overriding limitation of this study is the small number of 
experimental repeats performed which may mean observed 
changes have arisen due to random chance. Furthermore, breast 
cancer is clinically heterogeneous, with combinations of expressed 
receptors varying greatly and co-expression (or lack of) of notable 
signi"cance. This study investigated only one cell line, MCF-7, 
which restricts the generalisability of conclusions drawn from 
the data. Future studies utilising other cell lines would thus be of 
value. Investigation of other hormonal therapies is also warranted, 
and particularly tamoxifen given its widespread use. Similarly, the 
widespread use of dexamethasone as an adjuvant therapy compels 
investigation into the biological changes this may be evoking. 
In conclusion, the present study demonstrates signi"cantly 
increased GR protein in both fulvestrant-resistant and tamoxifen-
resistant MCF-7 cells, supporting the hypothesis that GR signalling 
may have a role in driving anti-hormone resistance in breast cancer.  
Given the implications of these data, and the scale of anti-hormone 
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Lysis Bu"er (100mL), pH 7.6
> Tris base (50mM)    0.61g
> EGTA (5mM)     0.19g 
> NaCl (150mM)      0.87g
> Triton (1%)     1ml
2X Laemmli Sample Bu"er (10mL)
> 10% sodium dodecyl sulphate (SDS)  4ml
> 20% glycerol     2ml
> Tris bu#er (0.5M, pH 6.8)                   2.4ml
> Distilled water     1.6ml
> Bromophenol blue    1mg
> Dithiothreitol (DTT)    15.4mg
7.5% Acrylamide Resolving Gel (10mL)
> Distilled water     4.8ml
> Tris bu#er (1.5M, pH 8.8)                   2.5ml
> 30% Acyrlamide solution    2.5ml
> 10% Sodium dodecyl sulphate (SDS)  0.1ml
> 10% Ammonium persuplhate (APS)                 0.1ml
> Tetramethylethylenediamine (TEMED)  6µl
4% Acrylamide Stacking Gel (10mL)
> Distilled water     6.1ml
> Tris bu#er (2.5M, pH 6.8)                   2.5ml
> 30% Acyrlamide solution                    1.3ml
> 10% Sodium dodecyl sulphate (SDS)  0.1ml
> 10% Ammonium persuplhate (APS)                 0.1ml
> Tetramethylethylenediamine (TEMED)  10µl
1X Running Bu"er (1L) 
> Tris base (0.25M)     3.02g
> Glycine (1.92M)     14.4g
> 0.1% sodium dodecyl sulphate (SDS)  1.0g
Transfer Bu"er (1L)
> Tris Base (0.25M)    3.03g
> Glycine (1.92M)     14.4g
> 20% Methanol     200ml









1X TBS-Tween (1L) 
> Tris base      1.21g
> NaCl                      5.8g
> HCl (5M, pH 7.6)     1.5ml
> Tween 20      0.5ml
Ponceau S stain: 0.1% (w/v) in 5% acetic acid
5% Milk: 1.5g Marvel skimmed milk powder in 30mL 1X TBS-Tween
1% Milk: 0.5g Marvel skimmed milk powder in 50mL 1X TBS-Tween
Detection Reagents (Pierce and Warriner Ltd., Chester, UK)
> SuperSignal West Pico Chemiluminescent Substrate
> SuperSignal West Dura Chemiluminescent Substrate
> SuperSignal West Femto Chemiluminescent Substrate
Reverse transcription PCR Mastermix Solutions 
> 5µl Deoxyribonucleotide Triphosphates (dNTP) (2.5mM)
> 4µl 5X PCR Bu#er 
> 2µl Random Hexamers (100µM) 
Reverse Transcription Cycling Parameters
• 22°C, 10 minutes (annealing)
• 42°C, 42 minutes (chain elongation)
• 95°C, 5 minutes (denaturing)
PCR Mastermix Solution 
• 18.75µl sterile RNA/DNAase free water
• 2.5µl 10X PCR bu#er (Fisher Scienti"c, Loughborough, UK)
• 2µl deoxyribonucleotide triphosphates (dNTP) (2.5mM stock)
• 0.625µl of each primer (20µM stock)
• 0.75ul MgCl (50mM stock)
• 0.2µl Taq DNA Polymerase (Fisher Scienti"c, Loughborough, UK)
PCR Primer Sequences
B-actin 
Forward: 5’  GGA GCA ATG ATC TTG ATC TT 
Reverse: 5’  TCC TGA GGT ACG GGT CCT TCC 
APPENDIX B 





Forward: 5’  TCT GAA CTT CCC TGG TCG AA    
Reverse: 5’  GTG GTC CTG TTG TTG CTG TT
PCR Cycling Parameters
1st Cycle
• 95°C, 2 minutes (denaturation)
• 55°C, 1 minute (annealing)
• 72°C, 5 minutes (chain elongation) 
Intermediate cycles 
• 94°C, 30 seconds
• 55°C, 1 minute
• 72°C, 1 minute
Final Cycle
• 94°C, 1 minute
• 55°C, 1 minute
• 60°C, 10 minutes
2% PCR agarose gel (50ml)
> Agarose      2g
> 1X Tris acetate-EDTA bu#er (TAE)    100ml
> RedSafe Nucleic Acid Staining Solution                   5µL
DNA loading bu"er
> 40% sucrose      4g
> Bromophenol blue (0.25%)    25mg 








Primary Antibody Solutions (Dilution of 1 in 1000 in 1% milk)





Antibody Animal origin species
GR Rabbit
E-actin Rabbit
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